|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Evet (Yes)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
05.04.2024
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
In our announcement dated 5 April 2024; it was disclosed to the public that a Share Purchase Agreement was signed in relation to the sale of our shares in Eczacıbaşı Monrol Nükleer Ürünler Sanayi ve Ticaret A.Ş. ("Eczacıbaşı-Monrol") corresponding to 50% of the issued share capital, to Curium International Trading B.V.("Buyer").
With regards to the Turkish Competition Authority ("TCA") approval, which is among the closing conditions stated in the aforementioned announcement, we have been informed that, within the scope of the application introduced by the Buyer to the TCA and as per the evaluation conducted by the Competition Board, it has been decided to take the relevant transaction into final examination in accordance with the first paragraph of Article 10 of Law No. 4054 on the Protection of Competition.
In this context, the process is ongoing, and developments regarding the matter will be shared with the public as necessary within the framework of the Capital Markets Legislation.
This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.
|
||||||||